---
title: "Enveric Biosciences | 8-K: FY2026 Q1 EPS: USD -1.08"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286561161.md"
datetime: "2026-05-15T12:02:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286561161.md)
  - [en](https://longbridge.com/en/news/286561161.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286561161.md)
---

# Enveric Biosciences | 8-K: FY2026 Q1 EPS: USD -1.08

EPS: As of FY2026 Q1, the actual value is USD -1.08.

#### Net Loss

Enveric Biosciences, Inc. reported a net loss attributable to stockholders of - $1.6 million for the first quarter ended March 31, 2026, which included - $0.1 million in net non-cash expense. This compares to a net loss of - $2.2 million for the quarter ended March 31, 2025, which included $0.3 million in net non-cash income.

#### Cash Position

As of March 31, 2026, Enveric Biosciences, Inc. had cash-on-hand of $4.9 million. As of May 15, 2026, the company’s cash balance was approximately $10.3 million.

#### Capital Raises

During the first quarter of 2026, Enveric Biosciences, Inc. raised gross proceeds of $2.8 million through offerings, including approximately $1.5 million from a registered direct offering. Subsequent to the first quarter, the company raised an additional approximately $1.5 million from the exercise of warrants. Enveric Biosciences, Inc. also closed a private placement expected to generate gross proceeds of up to $13.9 million, including $5 million received upfront and approximately $8.9 million in potential additional proceeds upon full exercise of warrants.

#### Operational Highlights

**Product Development:** Enveric Biosciences, Inc. continued the advancement of its lead candidate EB-003, with IND-enabling studies progressing toward a planned first-in-human clinical trial. Additional preclinical data for EB-003 demonstrated dual Gq and β-arrestin signaling at 5-HT2A. Subsequent to the first quarter, positive results for EB-003 highlighted a rapid reduction in conditioned fear response in a preclinical model of PTSD.

**Intellectual Property:** The company strengthened its intellectual property portfolio with new patent issuances and allowances across its EVM301 and EVM401 series. AbbVie, Inc. withdrew a Post-Grant Review petition filed against Enveric Biosciences, Inc.’s U.S. Patent No. 12,138,276. Enveric Biosciences, Inc. also enhanced patent claim coverage for its N-heterocycle substituted tryptamine derivative molecules for non-hallucinogenic treatment of neuropsychiatric conditions. Five of its trademarks, including Enveric and Enveric Biosciences, were registered with the Canadian Intellectual Property Office.

**Corporate & Business Development:** Enveric Biosciences, Inc. participated in a panel discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum. The company expanded its collaboration with TOTEC Pharma through a trademark license and option, out-licensing the RCANN™ trademark portfolio.

#### Outlook

Enveric Biosciences, Inc. anticipates that its current funds will support the completion of preclinical development activities for EB-003, the planned filing of an IND application, and operations into the first quarter of fiscal year 2027. The company remains focused on advancing EB-003 towards an IND submission and first-in-human clinical trials. Enveric Biosciences, Inc. believes it is well positioned to generate meaningful value for stockholders as it transitions toward the clinical phase of drug development.

### Related Stocks

- [ENVB.US](https://longbridge.com/en/quote/ENVB.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Richards Group Inc. Announces May 2026 Dividend | RPKIF Stock News](https://longbridge.com/en/news/286925142.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)